Berberine Suppresses SASP in Atherosclerosis via RXRα/PPARγ/NEDD4: Mechanistic Insights and Research Tools

Study Background and Research Question

Atherosclerosis, a chronic inflammatory disease of the arteries, is driven in part by the accumulation of senescent foam cells within vascular plaques. These aging cells exhibit the senescence-associated secretory phenotype (SASP), characterized by the persistent release of pro-inflammatory cytokines and other molecules that exacerbate tissue dysfunction and promote disease progression. While berberine (BBR), a plant-derived alkaloid, has shown anti-senescence properties, the molecular mechanisms underlying its actions in atherosclerotic models remain incompletely characterized. The central research question addressed by Zheng et al. (2025) is: How does berberine modulate inflammatory aging in atherosclerosis, particularly through nuclear receptor-mediated signaling pathways? (source; source)

Key Innovation from the Reference Study

The pivotal innovation of this study lies in the identification of the RXRα/PPARγ/NEDD4 pathway as a critical axis by which berberine exerts its anti-inflammatory effects in atherosclerosis. By integrating transcriptomic, cellular, and in vivo approaches, the authors demonstrate that berberine activates the RXRα/PPARγ heterodimer, which in turn upregulates NEDD4-mediated ubiquitination and degradation of the GATA4/p62 complex. This cascade effectively suppresses the production of SASP-related inflammatory proteins in macrophage-derived foam cells, directly linking berberine’s action to diminished chronic inflammation in vascular plaques (source).

Methods and Experimental Design Insights

The research employed a combination of in vivo and in vitro models to dissect the mechanistic effects of berberine on atherosclerotic inflammation:

• In Vivo Studies: ApoE^–/– mice, a standard model for atherosclerosis, were fed a high-fat diet with or without berberine administration. Lentiviral knockdown of RXRα in macrophages allowed for pathway-specific interrogation.
• Cellular Assays: RAW264.7 macrophages and peritoneal macrophage-derived foam cells were treated with berberine to assess effects on SASP-related protein expression and pathway activation.
• Single-Cell Transcriptomics: Smart-seq analysis identified transcriptional changes in response to berberine, focusing on genes associated with the RXRα/PPARγ/NEDD4 axis.
• Protein Interaction and Ubiquitination Assays: The interaction of GATA4 and p62, and their ubiquitination status, were analyzed to link pathway activation to functional protein turnover.

These methods enabled a multi-tiered mechanistic dissection from whole-animal outcomes to protein-level events.

Core Findings and Why They Matter

The central results of the study can be summarized as follows:

• Berberine Reduces SASP-Associated Inflammation: Treatment with berberine led to a significant reduction in SASP inflammatory markers in both mouse atherosclerotic plaques and cultured foam cells (source).
• Activation of RXRα/PPARγ/NEDD4 Pathway: Transcriptomic and immunological assays revealed that berberine activates the RXRα/PPARγ heterodimer, which increases NEDD4 transcription. NEDD4, an E3 ubiquitin ligase, promotes degradation of the GATA4/p62 complex, a driver of SASP protein production (source).
• Pathway Dependency Confirmed by Genetic Knockdown: The anti-inflammatory effect of berberine was abrogated in ApoE^–/– mice with macrophage-specific RXRα knockdown, confirming the necessity of this signaling axis.

These findings establish a mechanistic link between berberine, nuclear receptor signaling, and the modulation of inflammation via targeted protein ubiquitination. This axis represents a promising target for anti-inflammatory therapies in cardiovascular disease.

Comparison with Existing Internal Articles

Internal resources corroborate the centrality of the RXRα/PPARγ/NEDD4 axis in SASP modulation and provide additional context on the utility of pathway-specific inhibitors for mechanistic studies. For example, "Berberine Modulates RXRα/PPARγ/NEDD4 to Suppress SASP in Atherosclerosis" (summary) highlights similar mechanistic findings, affirming the reproducibility of berberine’s effects on macrophage foam cells. Meanwhile, articles such as "T0070907: Precision PPARγ Antagonist for Cell Signaling Studies" (summary) and "T0070907: A Precision PPARγ Antagonist for Advanced Cell Assays" (summary) discuss how selective PPARγ antagonists enable precise modulation of this pathway in cellular models, supporting the workflow strategies employed in the reference paper.

Protocol Parameters

• Cellular SASP inhibition assay | 1–10 μM berberine | RAW264.7 macrophages and foam cells | Empirically titrated for SASP suppression and pathway activation | paper
• PPARγ pathway modulation | 5–10 μM T0070907 | Adipogenic or macrophage models | Selective PPARγ inhibition to dissect pathway specificity | workflow_recommendation
• Ubiquitination detection | Standard E3 ligase activity protocols | Macrophage-derived foam cells | Used to confirm NEDD4-mediated GATA4/p62 degradation | paper
• RXRα knockdown | Lentiviral shRNA (pLVCD68-shRXRα) | ApoE–/– mouse plaques | Validates pathway dependency in vivo | paper

Limitations and Transferability

While the study provides compelling evidence for berberine’s action via RXRα/PPARγ/NEDD4 in murine and cell culture models, several limitations should be noted. The reliance on mouse models, despite their translational value, may not fully recapitulate the complexity of human atherosclerosis. Further, the precise dose–response relationships, long-term effects, and potential off-target consequences of berberine require additional investigation in preclinical and clinical settings. Additionally, while the role of PPARγ in adipogenesis and cancer biology is well established, this study’s focus is limited to vascular inflammation and does not address cross-domain effects beyond cardiovascular models (source).

Research Support Resources

To experimentally modulate the PPARγ signaling pathway in cellular models analogous to those described in this study, researchers may employ selective PPARγ antagonists. T0070907 (SKU A4301) is a potent PPARγ antagonist (IC50 1 nM) suitable for dissecting pathway-specific effects in studies of adipogenesis inhibition, PPARγ/RXRα heterodimer modulation, and cell cycle G2/M arrest (source: product_spec). T0070907 is available from APExBIO and can be integrated into workflows to validate the role of PPARγ in SASP-related inflammation and foam cell biology, as demonstrated in related research (workflow_recommendation).